Trial Search Results
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
The purpose of this study is to evaluate the safety, biological activity and pharmacodynamic effect of repeated intravitreal doses of hI-con1 0.3 mg administered as monotherapy and in combination with ranibizumab 0.5 mg compared to ranibizumab 0.5 mg monotherapy in treating patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
Stanford is currently not accepting patients for this trial.
Iconic Therapeutics, Inc.
- Biological: hI-con1
- Biological: ranibizumab
- Other: Sham injection
- Males or females of any race at least 50 years of age
- Active primary Choroidal Neovascularization (CNV) secondary to Age-Related Macular
Degeneration (AMD) in the study eye
- Best Corrected Visual Acuity (BCVA) of 70 to 24 letters (worse than 20/40 up to
20/320) in the study eye
- Monocular patient or patient with a BCVA of 35 or fewer letters (20/200 or worse) in
the better seeing eye
- Any prior treatment of CNV or advanced AMD in the study eye, except for dietary
supplements or vitamins
- Any intraocular or ocular surface surgery (including cataract surgery and laser
procedures) in the study eye within 3 months
- Vitrectomy in the study eye
- Hereditary or chronic hemorrhagic or coagulopathy conditions (i.e., hemophilia)
Ages Eligible for Study
50 Years - N/A
Genders Eligible for Study